Stockscreener 앱 받기
9.24
4.05%
-0.39
시간 외 거래:
9.06
-0.18
-1.95%
전일 마감가:
$9.63
열려 있는:
$9.64
하루 거래량:
1.05M
Relative Volume:
0.80
시가총액:
$787.47M
수익:
-
순이익/손실:
$-119.87M
주가수익비율:
-5.105
EPS:
-1.81
순현금흐름:
$-109.90M
1주 성능:
-8.70%
1개월 성능:
-11.41%
6개월 성능:
-24.57%
1년 성능:
+4.64%
1일 변동 폭
$9.03
$9.6602
1주일 범위
$9.03
$10.30
52주 변동 폭
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
9.24 | 841.96M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
Will a bounce in ORIC Pharmaceuticals Inc. offer an exitRisk Balanced Picks for Safer Trading - Newser
Will ORIC Pharmaceuticals Inc. continue its uptrendReal-Time Entry Forecast with Accuracy Metrics - Newser
What Fibonacci levels say about ORIC Pharmaceuticals Inc. reboundPrice Action Trading with Volume Confirmation - Newser
How to forecast ORIC Pharmaceuticals Inc. trends using time seriesPredictive System for Long-Term Stock Forecast - Newser
What data driven models say about ORIC Pharmaceuticals Inc.’s futureReal Stock Picks With Setup Verification - Newser
Is ORIC Pharmaceuticals Inc. a candidate for recovery playMonthly Long-Term Market Recap and Summary - Newser
Key resistance and support levels for ORIC Pharmaceuticals Inc.Bull Market Summary and Recovery Outlook - Newser
ORIC Pharmaceuticals Inc. stock momentum explainedEquity Signal Recap With Long-Term Summary - Newser
Is ORIC Pharmaceuticals Inc. a Top Dividend Stock to Watch in 2025In-Depth Stock Trading Volume Analysis - Newser
Using economic indicators to assess ORIC Pharmaceuticals Inc. potentialFree Risk Controlled Short Term Trade Plans - Newser
Vivo Capital LLC Purchases 802,632 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Volume spikes in ORIC Pharmaceuticals Inc. stock – what they meanFree Stock Market Watch With Alerts - Newser
Using data filters to optimize entry into ORIC Pharmaceuticals Inc.Weekly High Conviction Trade Setup Analysis - Newser
Oric Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - MarketBeat
Can ORIC Pharmaceuticals Inc. rally from current levelsFree Watchlist for Low Risk High Return - Newser
Using flow based indicators on ORIC Pharmaceuticals Inc.Smart Money Strategy for Growth Stocks - Newser
Oric Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Monday - Defense World
ORIC Pharmaceuticals ORIC 2025Q2 Earnings Preview Upside Potential Due to Innovative Drug Development - AInvest
How to manage a losing position in ORIC Pharmaceuticals Inc.Free AI Driven Buy Alert Trade Blueprint - Newser
Market reaction to ORIC Pharmaceuticals Inc.’s recent newsWatchlist Generator for Smart Money Signals - Newser
ORIC Pharmaceuticals Inc.’s volatility index tracking explainedOversold Reversal Picks with Buy Zone - Newser
Can swing trading help recover from ORIC Pharmaceuticals Inc. lossesFree Stock Screener With Smart Filters - Newser
How ORIC Pharmaceuticals Inc. stock performs during market volatilityShort-Term Growth Watch with Signal Prediction - Newser
What makes ORIC Pharmaceuticals Inc. stock price move sharplyDaily Market Momentum Summary and Strategy - Newser
Will ORIC Pharmaceuticals Inc. stock recover after recent dropFree Trade Setups With Clear Risk Limits - Newser
ORIC Pharmaceuticals: What It Takes To Be Best In Class (NASDAQ:ORIC) - Seeking Alpha
Is it too late to sell ORIC Pharmaceuticals Inc.AI-Powered Stock Trend Movement Analysis - Newser
ORIC Pharmaceuticals Shares Rally 20% on Encouraging Cancer Drug Trial and Funding Update - MSN
Price momentum metrics for ORIC Pharmaceuticals Inc. explainedFree Low Risk Picks for Daily Trading - Newser
Chart Analysts Warn of Resistance Near ORIC Pharmaceuticals Inc. PriceLow Volatility Stable Growth Picks Rank High - metal.it
Victory Capital Management Inc. Boosts Stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Visualizing ORIC Pharmaceuticals Inc. stock with heatmapsEquity Signal Recap With Long-Term Summary - Newser
Does ORIC Pharmaceuticals Inc. stock perform well during market downturnsMarket-crushing stock picks - Jammu Links News
ORIC Pharmaceuticals Awards Inducement Equity Grants to New Employees - AInvest
Analysts Set Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) PT at $18.57 - MarketBeat
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):